Cargando…
SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes
Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organi...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321248/ https://www.ncbi.nlm.nih.gov/pubmed/35891215 http://dx.doi.org/10.3390/vaccines10071051 |
| _version_ | 1784755994986807296 |
|---|---|
| author | Aguilera, Ximena Hormazábal, Juan Vial, Cecilia Cortes, Lina Jimena González, Claudia Rubilar, Paola Apablaza, Mauricio Ramírez-Santana, Muriel Icaza, Gloria Nuñez-Franz, Loreto Castillo-Laborde, Carla Ramírez-Riffo, Carolina Pérez, Claudia Quezada-Gate, Rubén Said, Macarena Vial, Pablo |
| author_facet | Aguilera, Ximena Hormazábal, Juan Vial, Cecilia Cortes, Lina Jimena González, Claudia Rubilar, Paola Apablaza, Mauricio Ramírez-Santana, Muriel Icaza, Gloria Nuñez-Franz, Loreto Castillo-Laborde, Carla Ramírez-Riffo, Carolina Pérez, Claudia Quezada-Gate, Rubén Said, Macarena Vial, Pablo |
| author_sort | Aguilera, Ximena |
| collection | PubMed |
| description | Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response. |
| format | Online Article Text |
| id | pubmed-9321248 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93212482022-07-27 SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes Aguilera, Ximena Hormazábal, Juan Vial, Cecilia Cortes, Lina Jimena González, Claudia Rubilar, Paola Apablaza, Mauricio Ramírez-Santana, Muriel Icaza, Gloria Nuñez-Franz, Loreto Castillo-Laborde, Carla Ramírez-Riffo, Carolina Pérez, Claudia Quezada-Gate, Rubén Said, Macarena Vial, Pablo Vaccines (Basel) Brief Report Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response. MDPI 2022-06-30 /pmc/articles/PMC9321248/ /pubmed/35891215 http://dx.doi.org/10.3390/vaccines10071051 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Brief Report Aguilera, Ximena Hormazábal, Juan Vial, Cecilia Cortes, Lina Jimena González, Claudia Rubilar, Paola Apablaza, Mauricio Ramírez-Santana, Muriel Icaza, Gloria Nuñez-Franz, Loreto Castillo-Laborde, Carla Ramírez-Riffo, Carolina Pérez, Claudia Quezada-Gate, Rubén Said, Macarena Vial, Pablo SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes |
| title | SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes |
| title_full | SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes |
| title_fullStr | SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes |
| title_full_unstemmed | SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes |
| title_short | SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes |
| title_sort | sars-cov-2 neutralizing antibodies in chile after a vaccination campaign with five different schemes |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321248/ https://www.ncbi.nlm.nih.gov/pubmed/35891215 http://dx.doi.org/10.3390/vaccines10071051 |
| work_keys_str_mv | AT aguileraximena sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT hormazabaljuan sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT vialcecilia sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT corteslinajimena sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT gonzalezclaudia sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT rubilarpaola sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT apablazamauricio sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT ramirezsantanamuriel sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT icazagloria sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT nunezfranzloreto sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT castillolabordecarla sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT ramirezriffocarolina sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT perezclaudia sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT quezadagateruben sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT saidmacarena sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes AT vialpablo sarscov2neutralizingantibodiesinchileafteravaccinationcampaignwithfivedifferentschemes |